http://ianlafo.com/figure-drug-store/
Figure Drug Store
I had a mold made of a dental night guard, has anyone lost teeth mold making?
Finally broke down and began the process for one night tooth guard. They kept telling me to get one but the price ($ 265 for soft) prevented me from achieving this. After going for cleanings every 3 months, so I thought maybe I should get one. I had bought a local drug store for about $ 30 to microwave it and then put in cold water but when I try to mold a hole with my molars. So it was time fugured. However, when I went to get the cast I was struck by the way the material drive is, how it felt like I was in my throat and I choak. And, when to put it outside it was like really taking advantage and I thought my teeth out with him, and I lose my crown, I had already had an apico on. My kids had these molds of their reinforcements, now I wonder how I could have submitted my children to this! So nobody has a bad experience with teeth falling out, choaking or anything else?
feels as if your teeth are pulled of your gums .. but that does not feel like they choke .. His panic if you ever have a mold done it again .. concentrate on their toes in again .. his mind on stuff I've never heard of any permanent damage to a mold of the mouth
To compare the role of drugs glyburide and pioglitazone in type 11 diabetes patients with non-insulin dependent diabetes mellitus
To compare the role of drugs glyburide and pioglitazone in type 11 non-insulin dependent diabetes mellitus patients.
Authors: Chohan Raj Kumar, Mashori Ghulam Rasool, Ghulam Rasool Bhurgri, Shamim-u-Rehman, DahriGhulam mustafa, Anis-u-Rehman.
Introduction: –
Diabetes comes from the Greek word for "siphon", which one is the first term and involves a large amount of urine is made. The TRM "mellitus" comes from a word brass, "known" which means "honey" and was used because the urine was sweet (Wheeler, 2004)
ketaocidosis diabetes is a life threatening condition requiring hospitalization and treatment have data. The recognition of this condition is almost important because even small delays can have an impact on survival (Nattrass, 2006). Hypoglycemia is involved in insulin-induced episodes in people with diabetes. Probably the main limitation factor, insulin treated patient to achieve the objectives of glucose necessary to prevent diabetic complications. The incidence of hypoglycemia reflects the current mathods inadequancy of delievery of insulin leading to insulin concentration ot inappropriately high, particularly for some people to eat more food after the onset of night blindness and also an important factor in disease risk heart and stroke
(Heller, 2003).
Diabetes mellitus TYPES
Type 1 diabetes mellitus (IDDM):
Type I diabetes affecting children of all ages, both sexes and all groups athenic. Type January is usually caused by mechanisms. Metabolic condition is more common in children and adolescents (Bui, 2004). Type1diabetes is characterized by immune destruction mediated pancreatic b-cells resulting from insulin deficiency. This results in a common biochemical endpoint of hyperglycemia and the risk of ketoacidosis, but the clinical presentation varies widely depending on the speed and degree of b-cell failure (Lambert & Bingley. 2005).
Type II diabetes mellitus (NIDDM):
Type II diabetes is a complex metabolic disorder associated with, b-cells dysfunction and with different degrees of primary insulin resistance main pathogenic factors of insulin resistance leading to type 2 diabetes and decreased insulin secretion resulting from alterations in liver, skeletal muscle and pancreatic B-cells (Charles & Clark, 1996).
Gestational DIABETUS
:
Women who develop glucose intolerance in pregnancy and women with previously undiagnosed diabetes.
DIABETUS MELLITUS SECONDARY:
secondary diabetes due to pancreatic diseases endocrime system, genetic disorders, or exposure to chemical agents.
Diabetes type I – formerly known as insluin dependent diabetes mellitus (IDDM) is characterized by destruction of pancreatic beta cells that produce inslulin
Type I diabetes – formerly known as insulin-dependent diabetes (IDDM) is characterized by destruction of pancreatic beta cells that produce insulin.Type-1 diabetes occures more frequently in children and young adults but can occures at any age. (Anderson et al 2007).
Diabetes Type-11 is not straight uprward. A pancreas does not produce enough insulin. Liver to release too much glucose, muscle cells do not readily take in glucose. (Carreño 2008)
Many genetic factors involved in the development of new researchers diabetes.Because close genetic approach to the identification of all genes in each candidate therefore not dependent on insulin and insulin-dependent diabetes (Bernhard, 1995).
Women who have had gestational diabetes are more likely to develop Type-11diabetes themselves.Pergnant women with diabetes are another disadvantaged group.They need more intensive prenatal care and close monitoring of blood glucose, pressure pressure and weight. (Jawed2006)
In children, the weight of the progression of childhood obesity in adulthood is associated with early development of complications such as diabetes and cardiovascular disease.Type IgpG2 diabetes is the most common clinical diabetes accountingforabout 90% of cases, we are seeing an epidemic worldwide. 11diabetes mellitus is infectious due to the use of insulin, is often the result of excess body weight and physical inactivity (WHO 2007).
PREVALACES and IINCIDENCE
:
Diabetes mellitus increases with age, in 200 the prevalence of diabetes, was estimated at 0.19% of those under age 20 and 8.6% in persons> 20 years old.There consider geographic variation in the incidence of both type-1 and type-11 diabetes mellitus.Scavandinvian has the highest incidence of diabetes mellitus type-1 diabetes, for example, in Finland, the incidence is 35/100, 000 per year Pacific rim has a much lower rate in Japan and China the incidence is 1 to 3 / 100, 00 per year of type-1 diabetes mellitus, Northern Europe and the United States share an intermediate type (8to17/100, 000 per year). The prevalence of diabetes mellitus type 11 Diabeties is greater in certain Pacific islands, intermediate in countries like India and the United States, and relatively low in Russia and China.This variability is probably due to genetic factors, environmental factors and beharioral (Power 2005). Diabettes mellitus prevalence among the population also poses a different ethic in certain countries is common inall ethnic groups with increased prevalence age and more than 5% of individuals over age 65 have diabetes mellitus (David Owerback 1988). The worldwide prevalence of diabetes mellitus has increased dramatically prevalence during the past two type11 decades.The diabettes expected mellitus, type 11 diabetes mellitus is more prevalent in Spains American natives, African Americans and Asians, Pacific Islanders than in non-Hispanic whites, the incidence is essentially the same in women and men in all populations. Type 11 diabetes is becoming increasingly common because people are living longer, and the prevalence of diabetes increases with age is also seen more frequently now before the young, in association with childhood obesity rising prevalenceof but type11 diabetes remains nubers countries with estimated cases of diabetes in 2000and 2030.
Rank Country
2000 People with diabetes country (milloins)
Country
Individuals with diabtes 2030 (millions)
India
31.7
India
79.47
China
20.8
China
42.3
U.S.
17.7
U.S.
30.3
Indonesia
8.4
Indonesia
21.3
Japan
6.8
Pakistan
13.9
Pakistan
5.2
Brazil
11.3
Russian Federation
4.6
Bangladesh
11.1
Brazil
4.6
Japan
8.9
Italy
4.3
Philippines
7.8
Bangladesh
3.2
Egypt
6.7
(Wareham and FOROUHI 2OO6)
Pharmacological treatment of Diabetic mellitus
:
Biguanides lower blood glucose, increase and glucose uptake in skeletal muscle using non-reducing resistance to insulin and reducing hepatic glucose production (gluconeogenesis). Lower blood glucose, addionally denisity reduces LDL and very low denisity (LDL and VLDL), respectively. Metformin has a half life of about 3 hours and is excreted unchanged in the metformin urine.Clinically used in type 2 diabetes who are obese and who respond to treatment with diet alone.Adverse effects gastrointestinal disturbances occur dose-related, for example, anorexia, diarrhea, nausea, lactic acidosis toxic effect rare but potentially fatal. (Dale, 2003).
Improve insulin sensitivity by activating certain genes involved in the synthesis of fat and carbohydrate metabolism and Piogiltazone Rosigilitazone approved.Thiazolidinediones now. Thiazolidinediones do not cause hypoglycemia when used alone, although usually taken in combination with sulfonylureas.
Incouraging In some studies, thaiazolidiniones have produced very favorable effects on the heart, including reducing blood pressure and triglycerides and improving cholesterol levels including increased level of HDL, good cholesterol. You can also block a molecule called 11 Best HSK can play a significant role in metabolic syndrome and type11 diabetes. One study even sugessted that rosiglitazone may improve beta cell function and thus help prevent the progression of diabetes.Anemia, weight gain, increased risk of fluid buildup can worson failure.Troglitazone heart was removed after some reports of heart failure abd failure.Liver Thiazoldinediones death.Current Don did not seem to have the same effects in the liver, although there have been some reports of liver damage.
In Failure to patients with special diets to the election of a sulfonylurea agent or insulin therapy has been controversial and empric for insulin therapy are the studies, who reported marked improvement after diagnostic receptor after short-term intensive therapy in type 2 diabetes mellitus treated (Scarlett et al, 1984) Sulfonylureas classified into two groups or generations on the basis of its potency, duration, drug interaction, the effects of the side rails. Sulfonylureas Improve Action of insulin in cultured cells and stimulates the synthesis of glucose transporters (Jacob et al 1998.) Drug sulfonylurea insulin secretion normally of choice NICE (National Institute for Clinical Excellence) also recommended that a generic drug should be perscribed (Scsade et al1998).
RESEARCH DESIGN AND METHODS:
This study was conducted in the deprtment of Pharmacololgy and Therapeutics, Basic Medical Sciences Institute, Jinnah Postgraduate Medical Centre, Karachi under the supervision of RRD od type: GhulamRsool Mashori, Associate Professir and Head of the Department of Pharmacology and Therapeutics in colloboration with medical outpatient clinic Unit111 Department and the filter, Department of Medicine, CCPE, Karachi.
Seventy NIDDM (type II) diabetic patients were initially enrolled in the study of clinical input and output filter of the patient Department of Medical Unit III, and this clinic.Out 60 diabetic patients were associated with diabetes in the study period, 10 patients were withdrawn because of other to change poor comlpiance residential place.All patients were divided into two main groups, groupies and group II patients were selected in this study agreement inclusion and exclusion criteria.
INCLUSION CRITERIA
:
- Recently diagnosed patients with non-insulin dependent mellitus Diabtes.
- Diagnsed diabetes patients that also includes drugs who have no history.
- Having both sexes aged between 30 and 60.
- patients who were diagnosed non-insulin diabetes mellitus Depedent treated with pioglitazone.
- Diagnosed patients who Depedent Imsulin Mellitus who were treated with drug glibenclamide.
EXCLUSION CRIRERIA
:
- Patients who suffer from blood pressure.
- Patients suffering from liver disease.
- Patients suffering from heart disease.
- Pregnancy and nursing mothers.
- Patients suffering from renal disorders.
- Patients with serious complications.
MATERIAL:
- Lacets.
- Lancet Hlder (TM2 easy Abades tactfully ASEE 03).
- Glucometer (Medisense) optilim a touch (Abbott).
- Blood glucose trpis nest (IVD for use vitro diagnostic (Abbott Labortries, Medisense UK Ltd, Abigngdon, Ox14ITR, Masd in the United Kingdom). stored at least 30?, (4 ° -30 ° C) and maximum 40 ° C (39 ° -86 ° F).
- Weight of Lot No 1101 model of the machine No.312. TANTIATA.
DRUGS
Match: Daonil 5 mg (Aventis Pharma)
category of drugs: sulfonylureas.
Generic Name: glyburide.
MFGLIC: RegistrationNO.000220 No.000007
MFG Date: 0-06
EXP Date :7-10
Lot No: b230
Match: Pioz (Hilton Pharm) PvtLTd.
Tab: 15 mg Poizer
Drug Category: Thaiazolinedione.
Generic name: pioglitazone hydrochloride.
MFG LIC: O.000136 Registration No.03270
MFG Date :3-06
EXP Date :3-o9
Lot No: 6287
Match: Poizer (Hilton Pharma) pvt ltd.
PARAMETERS:
Fasting blood sugar (FBS).
Random blood sugar (RBS).
Weight.
Key words: Diabetes mellitus, diabetes mellitus diabetes, diabetes mellitus insulin depedent, Daonil, poizer, insulin.
RESULTS:
Table 1
The weight and level of blood sugar observed in the reference date 0
In group 1 and group11
Group 1
Group 11
Pioglitazone n = 27
Glibenclamide n = 33
Weight
63.37
+ 2.25
¯
62.7
+ 15.56
¯
Fasting Blood Sugar
172.7
+ 13.32
¯
188.42
+ 12.o5
¯
Random blood
285.11
+ 15 0532
¯
284.18
+ 7.17
¯
All values are expressed as means ± SEM.
FIGURE-1 weight and levels of blood sugar observed in baseline (day-o)
Table N º shpwing weight (KG) and blood sugar (msg/dl0 levels observed on baseline (day-0) in both groups 9group: 1 and group11)
Group: 1 Weight (Kg's) mean ± SEM) is 63.37 ± 2.25 in fasting blood sugar 172.7 ± 13.32 and chance
blood sugar 285.11 ± 15.32
Group: 11
Weight (KG's0 (mean + SEM) 62.7 ± 1.56 Fasting blood sugar (188.42 12.05 ± mg/dl0, random blood sugar is 284.18 ± 17.03.
Figure 2: showing weight and levels of blood sugar observed at baseline (day-0) in group 1 and 11 weight 9kg group) their values are 63.37,62.7, fasting blood glucose (mg / dl) is 172.71, 188.42 of sugar Random blood (mg / dl) is 285.11 and 284.18.
TABLE: 2
Comment Peroidic all scores of Group 1
Goup1 (Pioglitazone) n = 27
P-value
Day-0
Day-45
Day-90
Day-0to45
-Day 45-90
Weight
63.37
± 2.25
63.63
± 2.26
63.63
± 2.23
> 0.05
(NS)
> 0.05
(NS)
Fasting blood sugar
172.7
± 13.32
165.04
± 8.98
153.37
± 7.59
> 0.05
(NS)
0.05
(NS)
Randomblood sugar
285.11
± 15.32
279.78
± 13.63
255.56
± 12.65
> 0.05
(NS)
> 0.05
(NS)
All values are expressed as mean ± SEM. (NS) not significant.
TABLE NO: 2
Regular observations are shown in all parameters in group 1 (piogiltazone) (n 27) Weight P.value (day 0 to day 45)> 0.05 (NS). Glucose glucose> 0.05 (NS) of random blood sugar> 0.05 (NS) 90 days P.values weight> 0.05 (NS), FBS> 0.05 (NS) 7RBS> 0.05 (NS) Not Meaningful
FIGURE: 2 Showing regular observation in all parameters in group 1 in day0 90.Mean 45 and weight values (Kg) is 63.37,63.26,63.63, fbs (mg / dl) 172.7,165.04,153.37, RBS (mg / dl) 285.11,279.78,255.56.
TABLE NO3
Observation in all parameters Peroidic Group11
Group 11 (glibenclamide)
N = 33
P-value
Day-0
Day-45
Day-90
Day-0-45
-Day 45-90
Weight
62.7
± 1.56
65.64
± 2.10
64.55
± 1.92
> 0.05 (NS)
0.05 (NS0
Fasting blood sugar
188.42
± 12.05
168.45
± 10.99
140.06
± 5.68
> 0.05 (NS)
> 0.05 (S)
Random blood sugar
284.18
± 17.03
220.12
± 13.39
170.94
± 5.80
<0.005 (MS)
0.002 (MS0
(S) major, (MS) significantly moderate
All values are expressed as mean ± SEM.
Chart 3:
Showing observation periodically in all parameters Goup: 11 Group: 11 containing the drug (glibenclamide), no patients (n = 33). P-value is the day 0 to day Weight 45> 0,05 (NS), FBS> 0.05 (NS) RBS <0.005 (MS) <0.01-AND DAY TO DAY WEIGHT 45 90> 0.05 (NS) FBS (0.05) RBS <0.002 (Moderately important M.S0.
Figure 3: Shwing regular observations in all parameters in Group 11 Weight 62.7,65.64,64.55, FBS (mg / dL) 188.42,168.45 140.06, RBS (mg / dl) 284.18 220.12, 170.94 (on day-0-day 45 to 90).
DISCUSSION:
In Denmark, the Nielsenet Beck, Skillman TG (1981) published studies that glyburide Demonstration, increased the number of receptors on monocytes of patients with diabetes mellitus type 11. Some patients were treated with diet and second-generation cobination sulfonyureas Wie agents. The number of insulin receptors in all patients were measured before and after the glucose test treatment.Intrvenous impairent shows continued afterthe that the secretion of insulin from drug therapy.However patients who were on pioglitazone some results have been obtained from the secretion of insulin degradation drug in the first therapy.Clinical observations have suggested that second-generation sulfonylureas may exert their effects by enhancing the insulin released by other stimulators primary drug of insulin secretion.
According to the study of WilliamC Dukworth et al (1972), aftr chronic treatment with sulfonylureas is well documented that plasma insulin levels were reduced in response to oral glucose. This, apparently, although it occures glucose tolerance is improved pre-treatment levels, this study clearly support this study.
The result of the group og 11 correlates with research by Bonnie & Kimmel (2005) produces the same results as reduced FBS from the beginning and end of the study, with an overall 23.44% reduction, while the results end of the study showed the value of p peroid were (p <0.001).
Similarly, Michael Alvarsson et al (2003) conducted a similar type of study and found global changes and 22.11% change in fibroblasts and 40.88% in RBS after the trial of value-se (p <0.001).
However, one study (Stone & Brown (2003) didnot agree with our results in the parameter of the FBS and the observer a reduction of 26.22%.
CONCLUSION:
The results of the discussion is obiovus study glibenclamide was more effective, tolerable and safer than a short duration.Diabetes pioglitzone Mellitus is to prolong the disease for life.Poor community can afford it easily, on the basis of marketing of this drug in patients with diabetes easy to go shopping pakistan economically, in fact, mostly people buy at the pharmacy without perscription dr because pharmaceutical and the patient, both knowledge about this disease.Just as dispirin as an analgesic, is known diabetes drug in our states, compared to other drugs antidiabetics.
REFERNCES:
- Anderson J, Kendall, Perryman.S et al, "Diet and Diabettes" Diabetes 2006.16 (3) :17-19-
- Bui H-Type 1 diabetes in childhood-Medicine ,1-3 2006.3
- Bernhard-type 11 diabetes mellitus diabetes diabetes care 1995.19 (100:12-17-
- Clark CM-oral therapyin type11 pharmacological properties diabetes and clinical use of the current use of spectrum currently available agents, Diabetes 1998.11 (4) :211-221.
- Carreño M. Types of Diabetes mellitus Diabettes-2006 10 (3), 07 –
- David Owerback NJ-The prevalence in the population for Diabetic 1988.02 (6) :31-32
- Dale MM, Treatment of Diabetes mellitus, pharmacology 20035th edition :287-391.
- Heller SR-Hypoglycemic ketoacidosis in diabetes and hypoglycemia Medicine-2006:34 (03) :102-110.
- F Jawad Untraveling the mystry Diabetes'Diabetes 2006, 15 (3) :13-15.
- Jacober D-insulin-Diabetes 1998, 6 (3) 1160126.
- Lambert and medicine Bingliy facts-base-2006, 34 (6) :3-7.
- M-Ketoacdosis Natters and hyperglycemia, Medicine 2006, 34 (3) :104-106.
- CA-Epidemiology of Diabetes type11 basic facts about diabetes Diabetes 2005, 1 (1) 7-9
- Scarlet oral treatment in Type Sulphonylureas 11 1984, 16 (10), 3-9.
- DS Schade et al A randomized placebo-controlled study of glimepiride in patients with diabetes mellitus Diabetes 19 998, 38 (7), 636-641.
- Forouhi-Epidimology Warchman and the basic facts Diabetes Diabetes, Medicine 2006, 34 (2), 57-60
- Wheeler discovery of Gd-Aaccident led to the Nobel Prize for Canadian researchers ,2005,01-02.
- Report of the WHO-Health-Diabetes Mellitus-Diabetes and types Defiition 2007, 1:1-4.
About the Author
working>as>assitant>professor>inmmc>mirpurkhas>sindh
